CSL Shares Marginally Higher on Influenza Vaccine Study Data

MT Newswires Live

11 hours ago

CSL's (ASX:CSL) shares inched higher in recent trading on Wednesday after it said on Tuesday that study data showed that relative vaccine effectiveness between adjuvanted quadrivalent influenza vaccines (aQIV) and high-dose quadrivalent influenza vaccines (HD-QIV) was comparable across all settings.

Findings were presented at the 10th European Scientific Working Group on Influenza conference in Valencia.

A test-negative design study in adults in the US aged 65 and above evaluated the relative effectiveness of aQIV versus HD-QIV in preventing influenza and related hospitalizations during the 2023 to 2024 season, including 37,377 vaccinated adults, with 3,174 testing positive for influenza.

A model-based analysis across Denmark, Sweden, Norway, and Finland evaluated the impact of extending enhanced influenza vaccine coverage to all adults aged 65 and older, which concluded that it would substantially reduce influenza-related doctor visits, emergency visits, and hospitalizations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2577438714"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577438714\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577438714?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-22 09:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577438714","market":"fut","top_or_hot":-1,"title":"CSL Shares Marginally Higher on Influenza Vaccine Study Data","media":"MT Newswires Live","content":"<html><body><p> CSL's (ASX:CSL) shares inched higher in recent trading on Wednesday after it said on Tuesday that study data showed that relative vaccine effectiveness between adjuvanted quadrivalent influenza vaccines (aQIV) and high-dose quadrivalent influenza vaccines (HD-QIV) was comparable across all settings.</p><p>Findings were presented at the 10th European Scientific Working Group on Influenza conference in Valencia.</p><p>A test-negative design study in adults in the US aged 65 and above evaluated the relative effectiveness of aQIV versus HD-QIV in preventing influenza and related hospitalizations during the 2023 to 2024 season, including 37,377 vaccinated adults, with 3,174 testing positive for influenza.</p><p>A model-based analysis across Denmark, Sweden, Norway, and Finland evaluated the impact of extending enhanced influenza vaccine coverage to all adults aged 65 and older, which concluded that it would substantially reduce influenza-related doctor visits, emergency visits, and hospitalizations.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSL Shares Marginally Higher on Influenza Vaccine Study Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSL Shares Marginally Higher on Influenza Vaccine Study Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-22 09:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> CSL's (ASX:CSL) shares inched higher in recent trading on Wednesday after it said on Tuesday that study data showed that relative vaccine effectiveness between adjuvanted quadrivalent influenza vaccines (aQIV) and high-dose quadrivalent influenza vaccines (HD-QIV) was comparable across all settings.</p><p>Findings were presented at the 10th European Scientific Working Group on Influenza conference in Valencia.</p><p>A test-negative design study in adults in the US aged 65 and above evaluated the relative effectiveness of aQIV versus HD-QIV in preventing influenza and related hospitalizations during the 2023 to 2024 season, including 37,377 vaccinated adults, with 3,174 testing positive for influenza.</p><p>A model-based analysis across Denmark, Sweden, Norway, and Finland evaluated the impact of extending enhanced influenza vaccine coverage to all adults aged 65 and older, which concluded that it would substantially reduce influenza-related doctor visits, emergency visits, and hospitalizations.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SGXZ23171101.USD","symbol_name":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2577438714","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577438714","pubTimestamp":1761097234,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"CSL's  shares inched higher in recent trading on Wednesday after it said on Tuesday that study data showed that relative vaccine effectiveness between adjuvanted quadrivalent influenza vaccines  and high-dose quadrivalent influenza vaccines  was comparable across all settings.Findings were presented at the 10th European Scientific Working Group on Influenza conference in Valencia.A test-negative design study in adults in the US aged 65 and above evaluated the relative effectiveness of aQIV versus HD-QIV in preventing influenza and related hospitalizations during the 2023 to 2024 season, including 37,377 vaccinated adults, with 3,174 testing positive for influenza.A model-based analysis across Denmark, Sweden, Norway, and Finland evaluated the impact of extending enhanced influenza vaccine coverage to all adults aged 65 and older, which concluded that it would substantially reduce influenza-related doctor visits, emergency visits, and hospitalizations.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","BK4086":"建筑产品","BK7501":"新冠治疗股","CSL":"卡莱尔伙伴","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","CSL.AU":"CSL LIMITED","BK7067":"生物科技","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK7508":"医药生物股","BK7511":"ESG概念","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC"},"translate_title":"CSL股价因流感疫苗研究数据小幅走高","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL":1.5,"CSL.AU":1.5},"content_text":"CSL's (ASX:CSL) shares inched higher in recent trading on Wednesday after it said on Tuesday that study data showed that relative vaccine effectiveness between adjuvanted quadrivalent influenza vaccines (aQIV) and high-dose quadrivalent influenza vaccines (HD-QIV) was comparable across all settings.Findings were presented at the 10th European Scientific Working Group on Influenza conference in Valencia.A test-negative design study in adults in the US aged 65 and above evaluated the relative effectiveness of aQIV versus HD-QIV in preventing influenza and related hospitalizations during the 2023 to 2024 season, including 37,377 vaccinated adults, with 3,174 testing positive for influenza.A model-based analysis across Denmark, Sweden, Norway, and Finland evaluated the impact of extending enhanced influenza vaccine coverage to all adults aged 65 and older, which concluded that it would substantially reduce influenza-related doctor visits, emergency visits, and hospitalizations.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}